Evidence map›Paper›PMID 39377811›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Preclinical evaluation and pilot clinical study of [

Yingfang He, Ruhua Tian, Dong Xu, Yanfei Wu, Sa Rina, Tengxiang Chen, Yihui Guan, Tianwu Xie, Tianlei Ying, Fang Xie and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Preclinical Evaluation of 5T4-Targeted [Journal of medicinal chemistry · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yingfang He *Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.
Ruhua Tian *Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China.
Dong Xu *Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Yanfei WuDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200233, China.
Sa RinaHuahe Pharmaceutical Co., Ltd, Shanghai, China.
Tengxiang ChenDepartment of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China.
Yihui GuanDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200233, China.
Tianwu XieInstitute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China.
Tianlei YingMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Engineering Research Center for Synthetic Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China. tlying@fudan.edu.cn.
Fang XieDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200233, China. fangxie@fudan.edu.cn.
Junbin HanInstitute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai, 200032, China. jhanoa@fudan.edu.cn.ORCID 0000-0002-2781-7710

Funding

National Natural Science Foundation of China 22171050National Natural Science Foundation of China 82302270Shanghai Municipal Health Commission GWV-11.1-40Shanghai Pujiang Program 23PJ1401500
6 · The paper itself

Abstract

purposeTrophoblast glycoprotein, the so-called 5T4, is an oncofetal antigen expressed in many different cancers. However, no 5T4-specific radioligand is employed in the clinic for non-invasive diagnosis. Thus, the aim of the current study was to develop a PET radiotracer for imaging 5T4 expression in preclinical and clinical stages.

methodsA VHH library was constructed by camel immunization. The specificity of the VHHs toward 5T4 antigen was screened through phage display biopanning and periplasmic extract enzyme-linked immunosorbent assay. 1,4,7-Triazacyclononane-1,4,7-triacetate acid (NOTA) derivative was conjugated to the selected VHH. After radiolabeling, microPET/CT and ex vivo biodistribution were conducted using BxPC-3 and MDA-MB-468 tumor-bearing mice. Cold VHH was co-injected with the tracer to challenge its binding in vivo. For the pilot clinical study, PET/CT images were acquired at 1 h after injection of tracer in patients with pathologically confirmed primary and metastatic tumors.

resultsA library with a capacity of 1.2 × 10

conclusions[

Indexed as

Gallium RadioisotopesHeterocyclic CompoundsHeterocyclic Compounds, 1-RingPositron-Emission TomographyPositron Emission Tomography Computed TomographyAnimalsCell Line, TumorFemaleHumansMicePilot ProjectsTissue Distribution1,4,7-triazacyclononane-N,N',N''-triacetic acidGallium-68Gallium RadioisotopesHeterocyclic CompoundsHeterocyclic Compounds, 1-Ring5T4Gallium-68Tracer developmentTrophoblast glycoprotein

Identifiers

PMID39377811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.